Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. Moreau told Proactive the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers, including both psychedelic experienced and psychedelic naïve subjects. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 17, 2023 11:25 AM Eastern Standard Time

Video

Unicycive: The Company Developing Key Kidney Therapies

Unicycive Therapeutics, Inc.

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. Unicycive is a biotechnology company focused on solutions for important and underserved renal diseases. The company currently has two key technologies in the development pipeline. UNI-494 works primarily to help the mitochondria in cells perform better, which in turn may help with Acute Kidney Injury (AKI). The company’s other technology, Renazorb, is currently being developed as an Investigative New Drug (IND). If approved, the drug will help patients significantly reduce their daily pill burden in the treatment of hyperphosphatemia. Watch the full interview here: Featured photo by Hal Gatewood on Unsplash Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

February 17, 2023 10:35 AM Eastern Standard Time

Video

Nation’s Transplant System Acts to Maximize Organ Use

United Network for Organ Sharing

United Network for Organ Sharing (UNOS), the non-profit that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN), is driving efforts to maximize organ acceptance and use. In its role as the OPTN, UNOS recently launched a predictive analytics tool, which adult kidney transplant programs can now use to augment decision-making and improve organ acceptance. Concurrently, the largest cohort of transplant organizations involved in an OPTN collaborative convened in Orlando, Florida recently to kick off a project focused on improving organ offer acceptance rates. The National Academies of Sciences, Engineering and Medicine (NASEM) recommended the use of predictive analytics as well as improving organ offer acceptance rates in their Feb. 2022 report on the nation’s organ donation and transplantation system. In 2022, 19.14% of all organs successfully recovered from selfless donors were not transplanted into a recipient, a statistic that UNOS is working with the entire organ donation and transplant community to improve. The new efforts signify important actions on behalf of the over 104,000 patients currently on the transplant waitlist. Predictive Analytics Tool This new tool shows physicians the predicted impact that accepting or declining a donor kidney offer could have on their patient, supplementing data already available to find the best-fit organ. This resource, offered to all adult kidney transplant programs across the country at no charge, aims to support decision-making, ultimately increasing the number of kidney transplants. Developed in collaboration with Accenture Federal Services, the tool is already providing physicians two key data points: the predicted length of time that their patient may wait for a similar kidney offer, and the patient’s likelihood of survival over the next three years without a transplant. “When we can use technology to supplement sound clinical judgement, we are best serving patients waiting for the gift of life,” said UNOS CEO Maureen McBride. “The new predictive analytics tool will help support the transplant teams making critical decisions on behalf of their patients.” Predictive analytics is the use of data, statistics and modeling to predict the likelihood of future outcomes. The NASEM report recommended using predictive data to improve organ acceptance rates in their 2022 recommendations. “Accenture is proud to be involved in the design and development of predictive analytics models which promise to improve offer acceptance in decision support tools,” said Accenture Federal Studio Design Director Ben Cannon. “We appreciate the willingness of the OPTN leadership to engage in a build-test-learn approach to address this challenge and for their close collaboration with specialists from various disciplines across both organizations - data science, human centered design, behavioral science, and technology. We are excited to continue our work and scale the predictive analytics program.” After a pilot phase that began in early 2022, UNOS used input provided by participating transplant programs to improve the tool before the national launch. An advisory panel will continue evaluating community feedback. Offer Acceptance Collaborative UNOS recently brought together transplant programs from a third of the country’s transplant hospitals to kick off the OPTN Offer Acceptance Collaborative in Orlando, Fla. The largest UNOS-led collaborative to date, this six-month effort focuses on improving responses to organ offers as well as defining and revising acceptance criteria. This collaborative will also help programs prepare for the use of a new offer acceptance metric to evaluate transplant program performance. UNOS will begin using this metric as a component of OPTN transplant program performance monitoring in July of this year. "If you look at the history of donation and transplantation, innovation is how we got here,” said Offer Acceptance Collaborative participant Deborah Maurer, who serves as Transplant Services Program Administrator at the University of Pittsburgh Medical Center. “It's our obligation to keep innovating, not just the scientific or clinical practices, but also the quality improvement processes and practices. This collaborative is a perfect example of giving the community the opportunity and mechanism to drive that innovation." Organ offers are an integral part of the nation’s organ donation and transplant system, but acceptance rates vary across the United States. The NASEM report identified offer acceptance as a “key area for improvement for transplant centers.” “UNOS is proud to convene transplant programs from across the country for this important collaborative project,” said McBride. “By strengthening our practices, constantly reevaluating what works as a community and asking tough questions about how and what we can do better, we can best serve the patients and families who rely on us.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

February 16, 2023 04:25 PM Eastern Standard Time

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Coya Therapeutics Inc.

By Ernest Dela Aglanu, Benzinga Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and commercialization of COYA 301 — the company’s low-dose IL-2 subcutaneous administration product candidate. For industry watchers, including investors, this might be very important, especially as multiple autoimmune diseases have largely unmet medical needs. A deep dive into the statistics by the American Autoimmune Related Diseases Association (AARDA) shows that an estimated ~50 million Americans have one or more autoimmune diseases. More worryingly, AARDA further said approximately 75% of those affected are women and tend to cluster in families, impacting multiple family members and generations. Autoimmune diseases are among the top 10 leading causes of death among American women. Expansion Of Its Exclusive Worldwide Rights The statistics around autoimmune diseases are certainly worrying. To help make a difference, players like Coya are actively ramping up and expanding their therapies to address the needs of the market. Coya just announced the expansion of their exclusive worldwide rights with ARScience Biotherapeutics Inc. for the development and commercialization of COYA 301, Coya’s low-dose IL-2 subcutaneous administration product candidate. Since 2020, the clinical-stage biotechnology company has been developing multiple therapeutic platforms to enhance T cell (Treg) function, including biologics and cell therapies. COYA 301 is an immunomodulatory cytokine for subcutaneous administration intended to enhance regulatory Treg function in vivo to treat the systemic and neuro-inflammation underlying certain autoimmune and neurodegenerative diseases. Under the expanded terms of the agreement with ARScience, Coya reports that it has been granted the rights to develop and commercialize COYA as a combination therapy across multiple therapeutic areas and disease conditions and as a monotherapy for various neurodegenerative disorders and autoimmune diseases. The company expatiated that these additional rights expand on the rights provided in the original license, which allowed Coya to develop and commercialize the product candidate as monotherapy for a number of neurodegenerative conditions and as a combination Treg-based therapy across multiple therapeutic areas. “We believe that Treg dysfunction is a common characteristic in certain neurodegenerative and autoimmune diseases. The expansion of the license agreement enables our development of COYA 301 in a potentially larger group of patients suffering from progressive diseases characterized by sustained inflammation,” Howard Berman, Ph.D., CEO of Coya, said in a statement. According to him, the company’s strategy is to develop COYA 301 as a monotherapy and in combination with other immunomodulatory drugs ( COYA 302 ) to potentially mitigate persistent inflammation. Carlos Banado, CEO of ARScience Biotherapeutics, also commenting on the licensing agreement, noted, “there is not currently an approved recombinant human low-dose IL-2 for therapeutic use. The development of a low-dose IL-2 formulation, delivered via a subcutaneous injection, may provide effective treatment in a wide range of diseases characterized by increased inflammation. We are confident that Coya Therapeutics has the expertise to develop and commercialize this asset in multiple indications, and we look forward to a successful collaboration.” The licensing agreement could be significant, especially as dysfunctional Tregs are the underlying cause behind numerous conditions, including neurodegenerative, metabolic and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in a lack of homeostasis of the immune system. Luckily, Coya says its investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. The company’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The expansion of exclusive worldwide licensing agreement could give Coya an edge while having a positive impact on the global autoimmune disease diagnostics market with players like Exagen Inc. (NASDAQ: XGN), Oncimmune Holdings PLC (LON: ONC), and Retromer Therapeutics. With the global market estimated to be worth $4.7 billion in 2021 and expected to reach about $8 billion by 2027 growing at a compound annual growth rate (CAGR) of 9.3%, the company appears well positioned for continued growth. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

February 16, 2023 09:15 AM Eastern Standard Time

Healixa Inc and WATERisLIFE Collaborate to Address the Global Water Scarcity Crisis with Global AquaDuct® Deposition Water Harvesting™ Technology

Healixa Inc.

McapmediaWire -- Healixa, Inc. (OTC: EMOR ) (“Healixa,” or the “Company”), a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water, and green-tech industries and WATERisLIFE, a global non-profit organization working to end the world water crisis, today announced their collaboration. The two organizations agreed to work together to respond to the growing water scarcity challenges in North America and internationally following recently completed demonstration of Healixa's proprietary Global AquaDuct® Deposition Water Harvesting™ Technology ("DWH ™ ") for multiple current and former US government officials and humanitarian experts. Healixa's DWH ™ technology is the world's first and only water vapor harvesting technology that can produce potable water directly from the earth's atmosphere by leveraging multiple proprietary advancements including phase-change, thermal deposition, and drawing operating power from on-grid or off-grid (solar) sources. Global AquaDuct® is a revolutionary approach to atmospheric water harvesting, providing a turnkey, sustainable, primary source of potable water in a compact form factor (only 12 sq. ft.), capable of directly addressing the significant limitations of competing technologies, to deliver substantially improved operational performance including energy efficiency, no relative humidity dependency, and constant reliable yield. Ken Surritte, Chairman, and founder of WATERisLIFE, said "Access to clean water is quickly becoming one of the most critical global challenges facing mankind. Water scarcity and droughts knows no borders and is increasingly threatening farmlands and communities in the developed world, just as it has in historically water-challenged geographies such as in Africa and the Middle East. Having seen first-hand the capabilities of Healixa's Global AquaDuct® technology, we believe this impressive and innovative solution has the potential to radically improve the lives of millions of people around the world. That is why are so excited to work with the Healixa team to showcase the impact that Global AquaDuct® can have in assisting communities around the global address their water insecurity challenges." "Healixa is dedicated to the development and commercialization of technologies that can positively impact the lives of millions. Having recently completed early-stage commercialization and testing of our Global AquaDuct® water harvesting technology, we are confident in its unmatched capabilities and potential. We are pleased to work alongside leading humanitarian organizations such as WATERisLIFE as we expand the awareness of our unique DWH ™ technology and advance our commercialization efforts with potential customers," added Ian Parker, Chairman and CEO of Healixa. About Healixa, Inc. Healixa is a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water generation and green-tech industries. Healixa embraces innovation by combining its intellectual properties, patents, strategic collaborations, and partnerships to create a "LaunchPad" of disruptive sustainable products. For more information, visit www.healixa.com. About WATERisLIFE WATERisLIFE is a 501 (c)(3) public charity bringing life-changing water solutions to the areas of the world that need it the most. For nearly two decades, WATERisLIFE has been working with the UN and the sustainability goals established by the UN for bringing safe water around the world. We aim to solve the world water crisis through better WASH (water, sanitation, and hygiene) programs in developing countries. WATERisLIFE brings cutting-edge technologies to the 47 countries we have been doing projects in. WATERisLIFE water, sanitation, and hygiene solutions have reached more than 60,000,000 people worldwide since inception. For more information, visit the website at www.WATERisLIFE.com Safe Harbor Statement Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Healixia Contact: Bret Hedges SVP of Strategic Partnerships 833-432-5492 Bret@healixa.com WATERisLIFE Contact: Director of Communications Cote@WATERisLIFE.com Contact Details Healixia Bret Hedges +1 833-432-5492 Bret@healixa.com WATERisLIFE Director of Communications Cote@WATERisLIFE.com

February 16, 2023 08:52 AM Eastern Standard Time

Faron Pharmaceuticals CMO "looking forward to a year filled with good data for the patients"

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief medical officer Marie-Louise Fjällskog updates Proactive's Thomas Warner the clinical-stage biopharmaceutical company's wholly-owned precision immunotherapy asset, Bexmarilimab. Fjällskog says that she's "looking forward to a year filled with good data for the patients." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 07:10 AM Eastern Standard Time

Video

Arecor Therapeutics "confident" in collaboration pipeline after another new deal

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the biopharma group has signed another collaboration deal with a top five pharmaceutical partner. The deal is the eighth of its type since the group’s listing in May 2021 and Howell says that she’s “confident” that the company will be announcing more such collaborations in the coming months. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 16, 2023 05:55 AM Eastern Standard Time

Video

News Release

BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Proactive's Steve Darling to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s red grape cell (RGC) composition to promote eye health. RGC is produced using BioHarvest's Botanical-Synthesis technology. Sobel told Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis-related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the US and about 2.5 million people worldwide have been diagnosed with MS. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 15, 2023 01:21 PM Eastern Standard Time

Video

Start the New Year with Cellular Energy Support

YourUpdateTV

For many, the holidays proved difficult for sticking to healthy routines. And it can be even harder to be motivated to prioritize your overall wellness throughout the year. But incorporating a healthy diet, exercise and supplements into your routine may help you work towards sticking to your New Year wellness goals. When your metabolism works optimally, it does a great job of supporting overall wellness. Recently, Dr. Nicole Avena, consultant for Jarrow Formulas, conducted a satellite media tour to share insights on how to support cellular energy production and gave tips on how to evaluate your daily nutrition and balance your diets with supplements such as vitamin B12. A video accompanying this announcement is available at: https://youtu.be/f7VxR7tOVSQ Ideally, we would all absorb optimal amounts of nutrients through a well-balanced diet – but this can be difficult to achieve. To support immune health, it’s important to evaluate daily nutrition and balance our diets with efficacious, scientifically based supplements. The Methyl B-12 from Jarrow Formulas, for example, is naturally recognized by your body, so it is delivered to your cells more effectively than a non-methyl B12 – all to support energy production at the cellular level.* Even more, Jarrow Formula’s Methyl B-12 is the perfect complement to a plant-based diet as it provides the same form of B12 found in animal-based food, and in a vegan chewable tablet. Methyl B-12 is a water-soluble vitamin and is the metabolically active and bioavailable form of vitamin B12 that helps support brain and nerve health, cellular energy production and sleep.* Together with folic acid, it also helps to reduce homocysteine levels to support good health.* Jarrow Formulas Methyl B12 is a vitamin supplement especially useful for vegetarians and people over 50 to help support adequate vitamin B12 levels. However, adequate Methyl B-12 status over the whole lifecycle is needed for optimal health. The suggested usage of our Methyl B-12 is to dissolve in mouth or chew 1 tablet per day or as directed by your qualified healthcare professional. Risk Factors for Vitamin B12 Deficiency Advancing age and diet are the primary risk factors for low vitamin B12 levels. It is recommended that people over 50 consider supplements and vitamin B12-fortified foods. Indeed, up to 40 percent of older individuals may have reduced stomach acid, which impairs absorption of vitamin B12.* Diet is a major risk factor for inadequate vitamin B12 levels. The best sources of vitamin B12 are animal products, such as meat, eggs, and fish. Therefore, strict vegetarians (those who eat no animal products) are at considerable risk. Jarrow Formulas has been carefully crafting vitamins, minerals and supplements since 1977. Informed by strong scientific research, Jarrow Formulas’ products have the potential to support and promote optimal health. For more information, visit Jarrow.com - *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. About Dr. Nicole Avena Dr. Nicole Avena is a research neuroscientist and a pioneer in the field of food addiction. Her seminal research work jump-started a new field of exploration in medicine and nutrition. She is an expert in diet during pregnancy and baby, toddler and childhood nutrition. Dr. Avena received a Ph.D. in Neuroscience and Psychology from Princeton University, followed by a postdoctoral fellowship in molecular biology at The Rockefeller University in New York City. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 15, 2023 12:20 PM Eastern Standard Time

Video

1 ... 160 161 162 163 164 ... 309